Cortice Biosciences Announces Upcoming Presentations at the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cortice Biosciences Announces Upcoming Presentations at the 2014 Cell Symposia for Translational Neuroscience and the Annual Meeting of the Society for Neuroscience

NEW YORK, Nov. 5, 2014 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that results from preclinical studies evaluating the activity of pipeline drug candidates CRT 001 and TPI 287 in models of neurodegenerative diseases will be presented at the 2014 Cell Symposia for Translational Neuroscience in Arlington, VA and the Annual Meeting of the Society for Neuroscience in Washington, D.C. Presentations include:

Title: Targeting beta1-adrenergic pathway as a novel approach to treat Alzheimer's disease

Date: Friday, November 14
Time: 1:00 – 2:30 PM ET 
Place: 2014 Cell Symposia for Translational Neuroscience
Poster: P2.59
Presenter: Mehrdad Shamloo, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Title: Role of beta1-adrenergic signaling in Alzheimer's disease (AD)

Date: Wednesday, November 19
Time: 8:00 AM - 12:00 PM ET
Place: 2014 Annual Meeting of the Society for Neuroscience
Poster #: 792.14/G4
Presenter: Mehrdad Shamloo, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Both presentations will include results demonstrating the ability of CRT 001 (xamoterol fumarate) to modulate cognitive behavior in animal models of Alzheimer's disease. Cortice plans to advance CRT 001 in clinical development in 2015 for treatment of one or more diseases associated with cognitive impairment.

Title: Effects of TPI 287, a novel taxoid, on a transgenic mouse model of Alzheimer's disease

Date: Wednesday, November 19
Time: 1:00 - 5:00 PM ET
Place: 2014 Annual Meeting of the Society for Neuroscience
Poster #: 691.12/C48
Presenter: Erwin Defensor, Ph.D., Stanford Behavioral and Functional Neuroscience Lab

Results demonstrating the ability of TPI 287, a brain-penetrable microtubule stabilizing agent, to improve cognitive performance in a mouse model of tauopathies will be presented. TPI 287 is currently being evaluated in Phase 1 clinical trials as a potential treatment for the orphan disease tauopathies, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), as well as Alzheimer's disease. 

About TPI 287

TPI 287 is a taxoid that binds to and stabilizes the assembly of microtubules similarly to the taxanes, paclitaxel and docetaxel. Compared with these other taxanes, TPI 287 has the distinct advantage of being able to readily penetrate the blood-brain barrier. Microtubule stabilization by TPI 287 in the brain may have potential as treatment of neurodegenerative diseases known as tauopathies that are associated with dysfunctional tau protein and defective microtubule architecture. Accordingly, TPI 287 is being developed for the treatment of the tauopathies progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Alzheimer's disease (AD). As an anti-cancer agent designed to inhibit cellular division and growth, TPI 287 is also being evaluated for the treatment of glioblastoma and secondary brain metastases.

About CRT 001

CRT 001 is a partial agonist of the beta1 adrenergic receptor, a family member of G-protein coupled receptors that control noradrenergic (NA) signaling, which is critical for learning and memory formation in mammals. NA signaling is also significantly disrupted in diseases associated with dementia, including Alzheimer's disease. CRT 001 was previously marketed in select European countries as xamoterol (Corwin) for the treatment of mild-to-moderate heart failure, and has been shown to be safe and well tolerated in over 70 published clinical trials that enrolled over 3,500 subjects. Based on this attractive clinical profile and highly compelling preclinical results, Cortice intends to develop CRT 001 for the treatment of diseases associated with cognitive impairment, which include Alzheimer's disease, Down syndrome, and several related orphan indications.    

About Cortice Biosciences

Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at www.corticebiosciences.com .

Safe Harbor Statement

This media release may contain forward-looking statements about Cortice Biosciences, which can be identified by the use of terminology such as "will," "would," "should," "expects," "anticipates," "intends," "plans," "believes," "may," "estimates," "predicts," "projects," or similar expressions intended to identify such statements. These statements reflect the current views of Cortice with respect to future events, are based on assumptions, and subject to risks and uncertainties.

Cortice Biosciences, Inc. 646-747-9090

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Norfolk Southern's 200-Year Campaign Meets a Hard Market

Updated Category News Views 0

Two centuries of railroad history can stir the blood, but it does not move a single carload by itself. Norfolk Southern has opened its 200-year railroading celebration with the GeneratioNS campaign, a three-locomotive NS 200 commemorative series, and plans for public events across its network. For a railroad with deep roots and very modern operational pressures, this is...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Stitch AI Targets Banking’s Hardest Automation Gap

Updated Category News Views 25

The flashy chatbot stuff is cheap; banking permission to act is not. That is why Stitch AI’s launch deserves more attention than another vendor slapping “agentic” on a slide deck and calling it transformation. Banks do not need a machine to summarize a policy document while everyone applauds the demo. They need technology that can touch real workflows without...

Continue Reading
UN Integrity Accelerator Targets Corporate Corruption

Updated Category News Views 91

Corruption rarely arrives wearing a villain costume; it shows up as a rushed payment, a friendly intermediary, or a contract nobody wants examined too closely. That is why the United Nations Global Compact's new Business Integrity Accelerator deserves a sober look. Launched November 18, 2026, the programme is not a magic shield, and nobody should sell it as one. But it...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 109

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading
Telit Cinterion Tests Its Defense Connectivity Pitch

Updated Category News Views 48

Defense connectivity is a messy business, and Telit Cinterion is leaning straight into the mess at NATO Edge 2026 in Izmir, Turkey. From November 17 through 19, the company is using Booth L86 to show how several wireless links can live inside one mission-focused setup. That may sound like standard trade-show wallpaper, but the underlying problem is very real: military and...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 85

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
Benicia's Bold Move to Streamline Permitting Pays Off

Updated Category News Views 196

Award-Winning Innovation from Benicia Benicia, California, shoots ahead of the pack by scooping up a highly coveted Helen Putnam Award for Excellence. Why? They chopped down bureaucracy like a lumberjack with a new ax by ushering in a digital revolution for their permitting process. Make no mistake, folks, this ain’t just a pat on the back—it's a blueprint for cities...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 75

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 102

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading

Top 5 Most Recently Viewed Articles

Broadwind to Host Q4 and Year-End 2024 Financial Results Call

Updated Category News Views 173

Broadwind Announces Financial Results Conference Call Broadwind (NASDAQ: BWEN), a prominent manufacturer in the clean tech sector, is preparing to share its financial performance for the fourth quarter and the entirety of 2024. The company will release its earnings report on March 5, just before the markets open. Investors and analysts alike are keen to gain insights into...

Continue Reading
Becker Milk Company Limited Shares Financial Highlights

Updated Category News Views 188

Becker Milk Company Limited Announces Financial Results Becker Milk Company Limited (TSX-BEK.B) recently announced its financial results for the quarter ended July 31, 2025. The company has demonstrated resilience in a competitive market while maintaining a commitment to its shareholders by declaring a regular dividend. Financial Performance Overview The financial results...

Continue Reading
Pembroke VCT Expedites B Ordinary Shares Issuance

Updated Category News Views 149

Pembroke VCT Enhances Shareholder Value with New Issuance Pembroke VCT plc has made a significant move by allotting 5,061,629 B Ordinary Shares through its current subscription offer, targeting a potential raise of £60 million in capital. These shares were priced between 102.23p to 108.24p, based on the unaudited net asset value from the end of September 2024. This...

Continue Reading
FASTSIGNS Convention 2025: Celebrating Franchise Growth

Updated Category News Views 472

FASTSIGNS 2025 International Convention Highlights Expert keynotes and engaging networking sessions took center stage at the recent FASTSIGNS International Convention. This year's theme, "Be All In," set an energizing tone for the event dedicated to honoring franchisee achievements and showcasing the brand's growth in sales, profitability, and locations. Attendance and...

Continue Reading
Pyxus International Gears Up for Earnings Call

Updated Category News Views 23

Pyxus Prepares for Earnings Call with Stakeholders In the tangled world of agricultural stocks, there's always one company that catches your eye when it's earning season, and right now, that's Pyxus International (OTCID: PYYX). This North Carolina-based player, a stalwart in the agricultural sector, has set the date to drop their financial numbers on June 4, 2026. Now, if...

Continue Reading